FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Completed Korean Phase 2 enrollment for its CAR-T and signed an exclusive Korean sales agreement with Chong Kun Dang.

  • Completed enrollment in the Korean Phase 2 trial of nespecel. Source
  • Announced a definitive agreement with Chong Kun Dang for exclusive Korean sales of nespecel. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

AbClon

Develops cancer antibodies and cell therapies using NEST, its platform for finding antibodies that bind new epitopes, and CAR-T technology.

Nespecel (AT101)

Phase 2

CD19 CAR-T using the company's own h1218 antibody; enrollment in its Korean Phase 2 trial in relapsed or refractory B-cell lymphoma was completed in July 2026, with an interim overall response rate of 94%.

AC101 (HLX22)

Phase 3

HER2-targeting antibody; partner Henlius is running a global Phase 3 trial in gastric cancer.

Completion reported

Signed a definitive agreement with Chong Kun Dang for exclusive Korean supply and sales of nespecel; AbClon handles approval, reimbursement and manufacturing, and Chong Kun Dang handles distribution and sales after approval.

Completion reported

Completed patient enrollment in the Korean Phase 2 trial of nespecel.

Completion reported

Completed a 12.2 billion won strategic investment from Chong Kun Dang.

Official role guide

AbClon careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 앱클론 ↗앱클론 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  2. 앱클론·종근당, CAR-T '네스페셀' 국내 독점 판매 계약 ↗메디파나뉴스 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  3. 종근당 전략적 투자를 위한 신주발행 및 납입완료 ↗앱클론 · Published 2025-05-19 · Sources checked 2026-11-18 · Original unavailable